ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prednisolone"

  • Abstract Number: L16 • 2019 ACR/ARP Annual Meeting

    GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

    Samuel Deshayes1, Venceslas Bourdin 2, Christian Creveuil 3, Jonathan Boutemy 1, Eric Liozon 4, Xavier Kyndt 5, Laurent Sailler 6, Grégory Pugnet 6, Hubert de Boysson 1, Eric Hachulla 7, Marc André 8, Julie Magnant 9, Jacques Boddaert 10, Olivier Fain 11, Arsène Mékinian 11, Mohamed Hamidou 12, Loïc Guillevin 13, Cédric Landron 14, Isabelle Marie 15, Yannick Chène 3, Laurent Becquemont 16, Céline Verstuyft 2 and Boris Bienvenu 17, 1Department of Internal Medicine, Caen University Hospital, Caen, France, 2INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, 3Biomedical Reserch Unit, Caen University Hospital, Caen, France, 4Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 5Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, 6Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 7Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, 8Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 9Department of Internal Medicine, Tours University Hospital, Tours, France, 10Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 11Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 12Department of Internal Medicine, Nantes University Hospital, Nantes, France, 13Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 14Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, 15Department of Internal Medicine, Rouen University Hospital, Rouen, France, 16INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, 17Department of Internal Medicine, Saint Joseph Hospital, Marseille, France

    Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
  • Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

    Mochihito Suzuki1, Toshihisa Kojima 2, Nobunori Takahashi 2, Shuji Asai 2 and Naoki Ishiguro 2, 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose:  In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
  • Abstract Number: 2656 • 2019 ACR/ARP Annual Meeting

    The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy

    Sarah Chung1, Meredith Morcos 2, Scott Pollock 1 and Bernard Ng 3, 1University of Washington Division of Rheumatology, Seattle, WA, 2University of Washington Division of Rheumatology, Seattle, 3University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA

    Background/Purpose: This study aimed to identify the incidence of ophthalmic complication of giant cell arteritis (GCA) among subjects with negative temporal artery biopsy (TAB) and to…
  • Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

    Sebastian H. Unizony1, Jinglan Pei2, Páris N. Sidiropoulos2, Jennie H. Best2, Christine Birchwood2 and John H. Stone3, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, CA, 3Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
  • Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting

    High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

    Sarah H. Chung1, Meredith B. Morcos1 and Bernard Ng1,2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…
  • Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting

    Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica

    Claire Owen1,2, Christopher McMaster2, David Liew1,2, Jessica Leung1,2, Andrew Scott3,4,5 and Russell Buchanan2,6, 1Medicine, University of Melbourne, Parkville VIC, Australia, 2Rheumatology, Austin Health, Heidelberg VIC, Australia, 3Medicine, University of Melbourne, Heidelberg VIC, Australia, 4Molecular Imaging and Therapy, Austin Health, Heidelberg VIC, Australia, 5Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg VIC, Australia, 6Medicine, University of Melbourne, Parkville, Australia

    Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…
  • Abstract Number: 896 • 2017 ACR/ARHP Annual Meeting

    The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis

    Jennifer Rodrigues1, David Collister1, Amy Archer2, Kim Cheema3, Paul Alexander4, Christian Pagnoux5, Lehana Thabane4, Peter A. Merkel6, David Jayne7 and Michael Walsh1, 1Nephrology, McMaster University, Hamilton, ON, Canada, 2Rheumatology, Northwestern University, Chicago, IL, 3Nephrology, University of Calgary, Calgary, AB, Canada, 4Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, 7Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Relapses of ANCA-associated vasculitis (AAV) are associated with death, decreased renal function, and end-stage renal disease.  Whether longer-term treatment with glucocorticoids (GC) reduces the…
  • Abstract Number: 930 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study

    Marianna Meroni1, Véronique Laure Ramoni2, Massimiliano Parodi3, Paolo Stobbione3 and Maurizio Cutolo4, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, 2Division of Rheumatology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, 3Rheumatology Unit, Internal Medicine Department, A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, Alessandria, Italy, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy

    Background/Purpose: Systemic lupus erythematosus (SLE) can affect young women and pregnancy still represents a challenge. Prednisone is safely used, at low doses (<7.5 mg daily),…
  • Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting

    Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry

    Dimitrios A. Pappas1, Chitra Karki1, Heather J. Litman1, Taylor Blachley1, Jessica L. Suboticki2, Jenny Griffith3 and Joel Kremer4, 1Corrona, LLC, Southborough, MA, 2AbbVie Inc., Mettawa, IL, 3AbbVie Inc., North Chicago, IL, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…
  • Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting

    Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice

    Dimitrios A. Pappas1, Carol J. Etzel2, Jennie Best3, Steve Zlotnick3, Taylor Blachley2, Gioia Persuitte2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting

    The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study

    Ronald F van Vollenhoven1, April Thompson2, Bonnie Pobiner2, Joe Eastman2, Anne Hammer2, James Groark3 and Damon Bass3, 1Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 2GSK Research Triangle Park, Research Triangle Park, NC, 3GSK Collegeville, Collegeville, PA

    Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
  • Abstract Number: 2734 • 2017 ACR/ARHP Annual Meeting

    A Comparison of Current Practice to New Vasculitis Treatment Guidelines

    Ishrat Gill1, Norman Madsen2, Imran Hassan3 and Elaine Yacyshyn4, 1Medicine, University of Alberta, Sherwood Park, AB, Canada, 2Medicine, Rheumatology, University of Alberta, Edmonton, AB, Canada, 3EPICORE Centre, University of Alberta, Edmonton, AB, Canada, 4Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Appropriate treatment for Anti-Neutrophilic Cytoplasm Antibodies (ANCA) Associated Vasculitis (AAV) requires induction and maintenance of remission, while balancing side effects from treatment. The CanVasc…
  • Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting

    Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)

    Soledad Retamozo1, Maria Jezabel Haye Salinas2, Juan Pablo Pirola3, Diego Baenas2, Ana C. Alvarez4, Veronica Saurit3, Alejandro Alvarellos5, Christian A. Waimann6, Gustavo Citera7,8, Fernando Dal Pra9, Celeste Orozco9, Federico Ceccato10, Sergio Paira10, MV Martire11, G Crespo Amaya11, Anastasia Secco11, M Mamani11, Javier Rosa12, Enrique Soriano12, Josefina Marcos13, Mercedes Argentina García14, Carolina Costi15, María M Zalazar16, Alejandro Martinez Muñoz16, Oscar Luis Rillo17, Horacio Berman18, Alberto Berman18, Francisco Colombres18, Edson Javier Velozo19, Vicente Ricardo Juarez20, M Crespo20, A Quinteros21, M Leal21, G Salvatierra22, Monica Sacnún23, R Quintana23, M Abdala24 and Francisco Caeiro25, 1Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, 2Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 3Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 4Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, 5Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 6Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, 7Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, 8Rheumatology, CONAART - IREP, Buenos Aires, Argentina, 9Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, 10Hospital Dr José María Cullen, Santa Fe, Argentina, 11Hospital Bernardino Rivadavia, CABA, Argentina, 12Hospital Italiano De Buenos Aires, CABA, Argentina, 13Hospital San Martin, La Plata, Argentina, 14Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 15Hospital San Martín, LaPlata, Argentina, 16Hospital Pirovano, CABA, Argentina, 17Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, 18Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, 19Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, 20Hospital Señor Del Milagro, Salta, Argentina, 21Centro Integral De Reumatología, Tucumán, Argentina, 22Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, 23Hospital Provincial De Rosario, Rosario, Argentina, 24Hospital Provincial Del Centenario, Rosario, Argentina, 25Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina

    Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
  • Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting

    Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk

    Katherine Liao1, Carol J. Etzel2,3, Jeffrey D. Greenberg4, Hongshu Guan5, Joel Kremer6 and Daniel H. Solomon7, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 2Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, 3Corrona, LLC, Southborough, MA, 4New York University School of Medicine, New York, NY, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6The Center for Rheumatology, Albany Medical College, Albany, NY, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
  • Abstract Number: 2162 • 2016 ACR/ARHP Annual Meeting

    Frequent Discussion of Insomnia and Weight Gain with Glucocorticoid Therapy: An Analysis of Twitter Posts

    Rikesh Patel1, Nabarun Dasgupta2, Maksim Belousov3, Meghna Jani4, Carly Winokur2, Goran Nenadic3 and William G Dixon1,5, 1Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 2Epidemico Inc., Boston, MA, 3School of Computer Sciences, The University of Manchester, Manchester, United Kingdom, 4Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Glucocorticoid (GC) therapy is used widely in patients with inflammatory diseases. However their effectiveness is offset by a range of potential harms. Clinicians and…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology